New Clinical Guide for Managing Direct Oral Anticoagulants (DOACs)

Wednesday | May 5, 2021 | 12:00 PM - 1:00 PM ET

The Anticoagulation Forum is very pleased to announce the publication of our new “DOAC Playbook”. This comprehensive guide provides practical information for clinicians who prescribe, monitor, and manage patients on DOACs. The DOAC Playbook includes clinical guidance on the following topics:

- Patient selection
- Periprocedural guidance
- Drug-drug interactions
- DOAC-associated bleeding
- Transitions of care
- Patient and family education
- And more!

Please join us for a webinar hosted by four of the DOAC Playbook authors highlighting this new AC Forum resource through patient case examples.

**Presenters**
- Arthur Allen, PharmD, CACP
- Jack Ansell, MD, MACP
- Sara Vazquez, PharmD, BCPS, CACP
- Diane Wirth, ANP CACP

**To Claim Credit (active on 5/05), just click on claim cme!**

Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation

Tuesday | May 25, 2021 | 12:00 PM - 1:00 PM ET
Direct oral anticoagulants (DOACs) are increasingly used in place of warfarin, but evidence about their effectiveness and safety in patients with valvular atrial fibrillation (AF) remains limited.

In this comparative effectiveness study using practice-based claims data, patients with valvular AF who were new users of DOACs had lower risks for ischemic stroke or systemic embolism and major bleeding than new users of warfarin. This data may be used to guide risk–benefit discussions regarding anticoagulant choices for patients with valvular AF.

Please join us for this webinar as the authors discuss the effectiveness and safety of DOACs compared with warfarin in patients with valvular AF.

**Authors:**
Geoffrey Barnes, MD, MSc
Adam Cuker, MD, MS
Ghadeer Dawwas, PhD, MSc, MBA

**Moderators:**
Arthur Allen, PharmD, CACP
Diane Wirth, ANP, CACP

---

**Vaccine-Induced Immune Thrombotic Thrombocytopenia:**
How it Happens and How to Spot It
Recorded on April 20, 2021

VITT is a very rare, treatable, vaccine-induced hypercoagulable state. First described only weeks ago, it is critical for clinicians to be able to recognize and treat this disorder. View the recording of the virtual grand rounds program hosted jointly by McMaster University and Anticoagulation Forum. Includes presentations by internationally recognized medical experts and the US Food and Drug Administration.

---

**Interested in viewing our enduring webinars?**

---

**Call for Stories!**
IDEA Initiative – Structural Racism & Health Disparities

The AC Forum Inclusion, Diversity, Equity, and Allyship (IDEA) Initiative is developing a multi-part webinar series to highlight the critical topic of structural racism and health disparities.

We are seeking both providers and patients to share their experiences on how racism has impacted them as they sought or provided healthcare.
If you are interested in telling your story or a story of one of your patients, please complete our brief survey. There will be an option to submit anonymously.

Deadline: May 19, 2021

Share Your Story

Learn more about the IDEA Initiative!

AC Forum National Conference

It is our pleasure to invite you to attend our 16th National Conference, which will be held in-person in San Francisco, CA from October 28-30, 2021, as well as broadcast virtually. Our forum provides the largest venue for open discussion and education on advances in anticoagulant therapy and improved patient care.

>> Learn More Here

Anticoagulation Forum Turns 30!

We are so excited to celebrate our 30 years of education and impact and to welcome our new president, Dr. Allison Burnett!!

Watch the video below to hear AC Forum leaders share their stories, experiences, and future goals for our organization!

30th ANNIVERSARY HIGHLIGHT VIDEO

Missed our 30th Anniversary Virtual Celebration? Check out the recording here to view the full presentation

Thank you all for who attended our celebration! As we previously mentioned all registrants were entered in a drawing for National Conference in October, the winner is Brian Schilling, PharmD!
Legislation for the *Pharmacy and Medically Underserved Areas Enhancement Act* was recently introduced in both the US House of Representatives (H.R. 2759) and the Senate (S. 1362). This bill will recognize pharmacists as health care providers for Medicare patients, granting pharmacists “provider status” and mandating pharmacists are fairly compensated for their patient care services.

As this legislation has the potential to expand patient access to clinical pharmacy services and improve the sustainability of anticoagulation-related services in underserved areas, we encourage the multi-disciplinary membership of the Anticoagulation Forum to support its passage.

The American Pharmacists Association has created a pre-written, editable advocacy alert that you may use to ask your U.S. Representative and Senators to co-sponsor the bill (H.R. 2759/S. 1362) or thank them if they have already signed on to the legislation. The form will automatically populate with the correct “please support” or “thank you” text based on your address.

As the field of anticoagulation continues to quickly evolve and become more nuanced, Rapid Resources aim to provide succinct one-page to two-page summaries to help providers stay informed. This library of compact info sheets is housed in the ACE Rapid Resources section located on the left of our ACE Resource Center. New materials are added regularly!

Here is the breakdown of new articles:
> April 19, 2021 update, 96 new articles, including 9 related to COVID-19
> May 5, 2021 update, 88 new articles, including 15 related to COVID-19

Supporting our Partners

The Anticoagulation Forum is dedicated to supporting our partners.

Want to know how you or your organization can partner with the Anticoagulation Forum? Email us at info@acforum.org
Thank You to Our Newsletter Sponsors

Janssen

Bristol Myers Squibb

Pfizer

ABIOMED

Recovering hearts. Saving lives.

Boston Scientific

Advancing science for life™

Acelis

Connected Health™

Instrumentation Laboratory

A Werfen Company